Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 12, 2017. The report details the publication of full results from Phase III clinical studies (METREX and METREO) for mepolizumab in patients with eosinophilic chronic obstructive pulmonary disease (COPD). The data was published in the New England Journal of Medicine and presented at the European Respiratory Society International Congress 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial results and regulatory strategy rather than financial performance.
Material Changes and Clinical Results
The primary material update concerns the efficacy of mepolizumab as an add-on therapy for COPD patients with high blood eosinophil counts:
- Primary Endpoint: In patients with blood eosinophil counts > 150 cells/µL at entry or > 300 cells/µL within the past year, mepolizumab (100mg) showed a consistent 18-20% reduction in the annual rate of moderate and severe exacerbations.
- Statistical Significance: The METREX study showed a statistically significant reduction (18%, p=0.036). The METREO study showed a 20% reduction that was not statistically significant (p=0.068).
- Biomarker Validation: A meta-analysis confirmed that exacerbation reduction rates increased as blood eosinophil counts increased, validating eosinophils as a biomarker for treatment response.
- Dose Response: No evidence of greater treatment effect was found with a higher 300mg dose compared to the 100mg dose.
- Non-Responders: Patients with blood eosinophil counts < 150 cells/µL did not benefit from the treatment.
Outlook, Risks, and Management Commentary
Regulatory Outlook: Based on the data and unmet medical need, GSK plans to submit regulatory filings for mepolizumab in COPD during 2017. The drug is not currently approved for COPD anywhere in the world.
Safety Profile: No new safety concerns were identified. Adverse event rates were similar between mepolizumab and placebo groups across both studies. Common adverse reactions included headache, injection site reactions, and back pain.
Management Commentary: Steve Yancey, GSK's Medicine Development Lead, emphasized the benefits of a personalized medicine approach using blood eosinophils as a biomarker. Professor Ian Pavord noted the clinical importance of exacerbation reduction for patients with no other treatment options.
Risks: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the company's 2016 Form 20-F.
Investor Verification Checklist
- Verify the timeline and status of the planned 2017 regulatory filings for mepolizumab in COPD.
- Confirm the specific patient population criteria (eosinophil thresholds) required for the proposed indication.
- Review the full safety data regarding hypersensitivity reactions and herpes zoster risks as detailed in the US Prescribing Information for Nucala.
- Assess the commercial potential of mepolizumab in COPD relative to its existing approval for severe eosinophilic asthma.
- Monitor for any updates on the secondary endpoints, which did not show significant differences in hospitalization rates or quality of life scores.